Leo Pharma poaches Orphazyme CEO
The CEO at Orphazyme will now take over the top job at Leo Pharma. It is the second time in one year that there is a CEO change at Orphazyme, where the CFO will now step in.
by victor emil kristensen, translated by catherine brett
Despite the fact that Christophe Bourdon was only appointed CEO at Orphazyme as recently as March 2021, he will be leaving the firm on April 1, 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme seeks shareholder support in future capital raise
For subscribers
Leo Pharma ends Boston bet
For subscribers
